Navigation Links
Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program
Date:12/4/2012

SUNNYVALE, Calif., Dec. 4, 2012 /PRNewswire/ -- Amarantus Bioscience, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed former Super Bowl Champion Toi Cook to its Board of Advisors. Mr. Cook will work with Company management to engage the National Football League (NFL), NFL Players Association (NFLPA) and individual retired players to raise awareness and funding for Amarantus' Coalition for Concussion Treatment (#C4CT) campaign, including the Company's MANF collaboration with Banyan Biomarkers that yielded positive data in Q2/2012.

"It's time to change the conversation about concussions and Traumatic Brain Injury in the NFL," said Toi Cook, Amarantus' newly appointed advisor. "We have been so focused on who is to blame for the rash of devastating results of brain injuries suffered while playing, that we have lost focus on the actual players who need help. Amarantus is working on breakthrough science that could ultimately treat concussions, brain injuries and their long-term side effects. This is the type of program that needs to be highlighted to the powers that be in the NFL and the NFLPA and we, as former players, need to be pushing the NFL and NFLPA to focus on providing support for research teams that are seeking to develop new treatments such as MANF that have the potential to fundamentally treat the devastating results of the brain injuries."

Mr. Cook had an 11 year career in the NFL, playing for the New Orleans Saints, San Francisco 49ers and Carolina Panthers. Mr. Cook had an interception as a defensive back in the 1994 Super Bowl championship for the San Francisco 49ers. Since retiring from the NFL, Mr. Cook has worked primarily in Sports and Entertainment. He was Executive Vice President in the Sports Division at the Gersh Agency in Los Angeles from 2004-2006. He is the principle at Toi Cook Management Group, LLC (TCMG), which has consulted for Broadband Sports, A2A Holdings and Dreier Sports. He is currently a plaintiff in a lawsuit of former NFL players against the NFL in relationship to concussions sustained while playing. He served as the Player Representative for the NFLPA for eight years when he was a player in the NFL. He was a football and baseball star at Stanford University, where he graduated in Communications after winning the College World Series in 1987.

"Toi will be a great addition to our Board of Advisors," said Gerald E. Commissiong, President & CEO of Amarantus. "He has deep-rooted connections into the NFL and the NFLPA at the highest levels, and understands the need to bring the various communities involved in Traumatic Brain Injury together in order to effect meaningful change in the conversation related to TBIs from a discourse about blame, to a discourse about finding solutions through medical science.  We will work together to bring the #C4CT program to the forefront of this discussion. There are treatments in development that need further support to ensure these programs have the necessary resources to move forward. We need leadership from groups like the NFL and NFLPA if we are to effect meaningful change in the area of TBI by bringing developers and patients together."

In recent years, the link between multiple concussions and long-term disability or brain disease has received significant scientific support. Recent studies have made clear scientific links between football-style hits and long-term brain diseases such as Parkinson's disease, Alzheimer's disease and Chronic Traumatic Encephalopathy. Increasing evidence supports the notion that mis-folded proteins play a critical role in the long-term side effects of concussions. Amarantus believes that MANF, which is selectively upregulated by glial cells in response to ischemia-induced neural injury and protects brain cells from chemically induced brain injury, will play a role in protecting brain cells from injury within the context of Traumatic Brain Injury.

About Amarantus Bioscience, Inc.

Amarantus Bioscience, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. This press release does not represent an offer to buy or sell securities.

Amarantus Bioscience, Inc.
(408) 737-2734
pr@amarantus.com

Investor/Media Contact:
IR Sense, LLC
Remy Bernarda
415-203-6386
remy@irsense.com


'/>"/>
SOURCE Amarantus Bioscience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
2. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
3. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
4. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
5. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
6. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
7. Amarantus BioSciences Secures $1.1 Million in Financing
8. Amarantus BioSciences Issues CEO Letter to Shareholders
9. Amarantus BioSciences Wins MANF Patent Challenge in Europe
10. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
11. Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
Breaking Biology News(10 mins):